Screen Shot 2021-01-12 at 11.44.35 AM.pn
  • HOME

  • TECHNOLOGY

  • PIPELINE

    • Overview
    • Oncology & Autoimmune
  • QUICK FACTS

  • LEADERSHIP

  • ADVISORY BOARD

  • NEWS

  • CONTACT

  • More

    Use tab to navigate through the menu items.

    A2A NEWS

    January 22, 2019

    PRESS RELEASE - A2A Pharmaceuticals Announces Fourth Quarter and Year End Results; Provides Business Update

    November 05, 2018

    A2A was a Finalist at RESI NYC Tech Hub Pitch Challenge

    October 25, 2018

    A2A Participated at the AI Applications Summit Biopharma Discussing the Urgency to Advance AI Applications in Industry to Bring Benefits to Patients Faster

    October 18, 2018

    A2A Founder & CEO Edward Painter was a Panelist at BIO Investor Forum Panel Entitled "Applying Artificial Intelligence to Improve Therapy Development Today"

    July 20, 2018

    Fierce Biotech: Insilico and A2A Launch New Duchenne-Focused AI Drug Company

    July 05, 2018

    PRESS RELEASE - A2A Pharma Provides Second Quarter 2018 Update

    June 21, 2018

    PRESS RELEASE - A2A Pharmaceuticals Takes Residency at JLABS@NYC

    February 06, 2018

    PRESS RELEASE - A2A Pharmaceuticals Investments Completed

    December 12, 2017

    A2A Wins AI Quickfire Challenge at JLABS @ Toronto

    February 27, 2017

    Irish Tech News - Innovative new biotechnologies showcased; IndieBio Demo Day reviewed

    January 24, 2017

    IndieBio - Designing Drugs In Silico: An Interview With Ed Painter of A2A Pharmaceuticals

    menu
    • HOME
    • TECHNOLOGY
    • PIPELINE
      • Overview
      • Oncology & Autoimmune
    • QUICK FACTS
    • LEADERSHIP
    • ADVISORY BOARD
    • NEWS
    • CONTACT
    Contact

    BioLabs New York
    180 Varick Street
    New York, NY 10014

    ​​​

    Cambridge Innovation Center
    1 Broadway 
    Cambridge, MA 02142
    Boston

    ​

    Info@Atoms2applications.com

    © 2019 A2A Pharma. All rights reserved